Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Follow-On Offering

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Follow-On Offering

Laidlaw & Company (UK) Ltd. is acting as co-manager for the offering.

© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

Site Info

Legal

Disclosures

Contact Info

Saylo Construction

Contact Us

Share

Site Info